Clinical Trial Update: Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial results for pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis have been posted, and the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Recurrent Respiratory Papillomatosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-07-03